IRWD Healthcare

Ironwood Pharmaceuticals, Inc.

$3.50+1.16%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 578.3M USD
Enterprise value: 698.7M USD
Full-time employees: 100

Overall health

Drawback: higher risk than most peers on debt, liquidity or share-price swings

Ranks #99 of 1,157 healthcare companies (top 9%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Ironwood Pharmaceuticals's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Ironwood Pharmaceuticals made a profit per share in its latest year after a loss the year before.
Valuation signals disagree. Cheaper than 95% of peers on earnings, but only 50% on free cash flow.
Relative to its earnings, Ironwood Pharmaceuticals looks cheaper than 95% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.
Profit is backed by cash. Free cash flow is 143% of reported profit.
Ironwood Pharmaceuticals's free cash flow is 143% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

73/ 100

Oct 5 73 → Nov 4 73

Valuation

Is the price right?

96/100

Strong

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Stronger than most peers on:

▲ Earnings yield
▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield22.5%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile30% base weight · Z-score 6.11Sector median: 0.0148 · MAD: 0.0148

EBITDA yield33.7%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile50% base weight · Z-score 3.69Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield32.1%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingOutlier capped at sector 5th/95th percentile20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-28.0%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

81/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 7.7%

Why

Stronger than most peers on:

▲ EPS growth
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-3.1%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -1.06Sector median: 0.0584 · MAD: 0.0840

Revenue growth26.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.06Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

99/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 4.8 points to 60.1%

Why

Stronger than most peers on:

▲ Operating margin
▲ ROA
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin60.1%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.16Sector median: 0.0706 · MAD: 0.1217

Return on assets45.5%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital138.3%

Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsOutlier capped at sector 5th/95th percentile33% base weight · Z-score 3.81Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin77.2%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.22

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 1.20Sector median: 0.6250 · MAD: 0.3380

Current ratio6.06×

SEC filings · latest balance sheetReported value33% base weight · Z-score 2.51Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Ironwood Pharmaceuticals

Is Ironwood Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 6, 2026) got stronger: operating margin rose 4.8 points to 60.1%. Its overall score is unchanged at 73/100 since Oct 28, 2026.
How is Ironwood Pharmaceuticals valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 96/100 against 1,393 healthcare peers. Earnings yield 22.5% vs a peer median of 1.5% (stronger than 95% of peers).Earnings yield 22.5% vs peers 1.5% (stronger than 95% of peers).
Is Ironwood Pharmaceuticals growing?: Yes, faster than most of its peers. Growth scores 81/100 against 1,393 healthcare peers. Revenue growth 26.2% vs a peer median of 6.1% (stronger than 84% of peers).Revenue growth 26.2% vs peers 6.1% (stronger than 84% of peers). 3-year revenue growth -3.1% vs a peer median of 5.8% (weaker than 78% of peers).3-year revenue growth -3.1% vs peers 5.8% (weaker than 78% of peers).
How profitable is Ironwood Pharmaceuticals?: More profitable than most of its peers. Profitability scores 99/100 against 1,393 healthcare peers. Operating margin 60.1% vs a peer median of 7.1% (stronger than 95% of peers).Operating margin 60.1% vs peers 7.1% (stronger than 95% of peers).
How risky is Ironwood Pharmaceuticals?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.22 vs a peer median of 0.63 (stronger than 89% of peers).Beta 0.22 vs peers 0.63 (stronger than 89% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 4.8 points to 60.1%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	361.5M USD	389.3M USD	+7.7%
Net income (12 months)	102.2M USD	129.9M USD	+27.1%
Operating margin	55.4%	60.1%	+4.8 pts
Cash	220.5M USD	79.1M USD	−64.1%
Shares outstanding	164.6M	165.2M	+0.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	—	—	—	—	—	—
Operating margin	56.1%	61.0%	-213.5%	26.5%	33.3%	▲ 6.8 pts
Net margin	127.7%	42.6%	-226.4%	0.3%	8.1%	▲ 7.9 pts
Return on assets (ROA)	46.9%	15.9%	-212.8%	0.3%	6.1%	▲ 5.8 pts
Return on equity (ROE)	87.2%	26.8%	—	—	—	—
Free cash flow margin	63.2%	66.6%	41.4%	29.4%	42.9%	▲ 13 pts
Current ratio	4.61×	30.58×	0.84×	4.69×	1.13×	▼ 76%
Debt to equity	0.75×	0.61×	—	—	—	—
Interest coverage	7.46×	32.95×	-43.71×	2.82×	3.01×	▲ 6.7%

IRWD price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Ironwood Pharmaceuticals's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

Ironwood Pharmaceuticals made a profit per share in its latest year after a loss the year before.

Valuation signals disagree. Cheaper than 95% of peers on earnings, but only 50% on free cash flow.

Relative to its earnings, Ironwood Pharmaceuticals looks cheaper than 95% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.

Profit is backed by cash. Free cash flow is 143% of reported profit.

Ironwood Pharmaceuticals's free cash flow is 143% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Ironwood Pharmaceuticals

Is Ironwood Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 6, 2026) got stronger: operating margin rose 4.8 points to 60.1%. Its overall score is unchanged at 73/100 since Oct 28, 2026.

How is Ironwood Pharmaceuticals valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 96/100 against 1,393 healthcare peers. Earnings yield 22.5% vs a peer median of 1.5% (stronger than 95% of peers).Earnings yield 22.5% vs peers 1.5% (stronger than 95% of peers).

Is Ironwood Pharmaceuticals growing?

Yes, faster than most of its peers. Growth scores 81/100 against 1,393 healthcare peers. Revenue growth 26.2% vs a peer median of 6.1% (stronger than 84% of peers).Revenue growth 26.2% vs peers 6.1% (stronger than 84% of peers). 3-year revenue growth -3.1% vs a peer median of 5.8% (weaker than 78% of peers).3-year revenue growth -3.1% vs peers 5.8% (weaker than 78% of peers).

How profitable is Ironwood Pharmaceuticals?

More profitable than most of its peers. Profitability scores 99/100 against 1,393 healthcare peers. Operating margin 60.1% vs a peer median of 7.1% (stronger than 95% of peers).Operating margin 60.1% vs peers 7.1% (stronger than 95% of peers).

How risky is Ironwood Pharmaceuticals?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.22 vs a peer median of 0.63 (stronger than 89% of peers).Beta 0.22 vs peers 0.63 (stronger than 89% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

361.5M USD

389.3M USD

+7.7%

Net income (12 months)

102.2M USD

129.9M USD

+27.1%

Operating margin

55.4%

60.1%

+4.8 pts

Cash

220.5M USD

79.1M USD

−64.1%

Shares outstanding

164.6M

165.2M

+0.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

—

Operating margin

56.1%

61.0%

-213.5%

26.5%

33.3%

▲ 6.8 pts

Net margin

127.7%

42.6%

-226.4%

0.3%

8.1%

▲ 7.9 pts

Return on assets (ROA)

46.9%

15.9%

-212.8%

0.3%

6.1%

▲ 5.8 pts

Return on equity (ROE)

87.2%

26.8%

—

Free cash flow margin

63.2%

66.6%

41.4%

29.4%

42.9%

▲ 13 pts

Current ratio

4.61×

30.58×

0.84×

4.69×

1.13×

▼ 76%

Debt to equity

0.75×

0.61×

—

Interest coverage

7.46×

32.95×

-43.71×

2.82×

3.01×

▲ 6.7%